CClinicalTrials.gg
CompletedNCT05396261Updated May 31, 2022

a Flexible Wound Dressing for the Management of Genital Skin Conditions

An interventional study of Film forming silicone gel (7-0940) in Vaginitis, Atrophic Vaginitis and Lichen Planus, sponsored by Stratpharma AG. Completed at 1 site in Australia. Open to female participants. Per ClinicalTrials.gov, last updated 2022-05-31.

Sponsored by Stratpharma AG · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Sex
Female
01

Study summary

The objective of the study is to determine the efficacy of 7-0940 in the management of genital skin conditions in female patients

02

Conditions studied

  • Vaginitis
  • Atrophic Vaginitis
  • Lichen Planus
  • Lichen Sclerosus
  • Menopause Related Conditions
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Able to provide informed consent
  • Diagnosed genital skin condition

Exclusion criteria

Exclusion Criteria:

  • Unable to give informed consent
  • Patient unable to apply topical device
  • Allergy or intolerance to ingredients or excipients of the formulation of studied products
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Treatment arm

    Film forming silicone gel (7-0940) is an innovative gel that forms a full contact, flexible wound dressing for supporting mucosal conditions of the genital, rectal and perineal areas. Film forming silicone gel (7-0940) is a semi-occlusive, non-resorbable, self-drying and transparent gel. Film forming silicone gel (7-0940) may be directly applied to dry, wet, cracked and sensitive mucosal tissue. Film forming silicone gel (7-0940) gel is bacteriostatic and inert. It contains no alcohols, parabens or fragrances.

    Device: Film forming silicone gel (7-0940)

Interventions

  • DeviceFilm forming silicone gel (7-0940)

    Anecdotal evidence suggests that genital conditions in women associated with vaginal atrophy improve with the use of film-forming silicone dressings.

05

What researchers measure

Primary outcomes

  1. gynaecological skin condition

    Likert scales to measure: * Dryness * Tissue thinning * Erosion/Ulcers * Fissures * Erythema * Scarring/adhesion * Contact bleeding * Bloodblisters * Greyish film * White lacy streaks

    Time frame: Duration of the therapy will be according to physician's clinical practice. The average is 3 visits over a period of 3 to 6 months

Secondary outcomes

  1. patient symptoms

    Likert scales to measure: * Pruritus/itchiness * Tender/sore * Swelling * Dryness * Burning of skin * Dyspareunia * Stinging with urination/clothes * Defecating pain/burning

    Time frame: Duration of the therapy will be according to physician's clinical practice. The average is 3 visits over a period of 3 to 6 months

06

Study locations

1 site
  • St. Andrews War Memorial Hospital
    Spring Hill, Queensland 4000, Australia
07

Registry details

Key details

Study ID
NCT05396261
Lead sponsor
Stratpharma AG
Responsible party
Sponsor
First posted
May 31, 2022
Start date
Jan 31, 2018
Primary completion
Jan 1, 2022
Completion
Feb 1, 2022
Last update
May 31, 2022

Study contacts

Philip Hall, MD
principal investigator · St. Andrews War Memorial Hospital - Australia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion